Search Results - F. Offner

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    P1215: PRELIMINARY PHASE 1/2 RESULTS OF SUBCUTANEOUS EPCORITAMAB + R-DHAX/C IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL... by R. Cordoba, L. Falchi, T. Phillips, S. de Vos, M. Nijland, F. Offner, I. Bykhovski, J. Wu, L. Wang, A. Rana, P. Abrisqueta

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  2. 2

    P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE by M. R. Clausen, F. Offner, D. Belada, J. Brody, K. M. Linton, Y. Karimi, R. Cordoba, S. Snauwaert, A. Abbas, L. Wang, J. Wu, B. Elliott, L. Falchi

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  3. 3

    S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HAS FAVORABLE SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AND ≥2 PRIOR THERAPIES: PIVOTAL PHA... by M. Dickinson, C. Carlo-Stella, F. Morschhauser, E. Bachy, P. Corradini, G. Iacoboni, C. Khan, T. Wróbel, F. Offner, M. Trněný, S.-J. Wu, G. Cartron, M. Hertzberg, A. Sureda, D. Perez-Callejo, L. Lundberg, J. Relf, E. Clark, K. Humphrey, M. Hutchings

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  4. 4

    P1105: FINAL RESULTS OF THE PHASE I/II HOVON124/ECWM-R2 STUDY INCLUDING 2-YEAR RITUXIMAB MAINTENANCE AFTER INDUCTION WITH IXAZOMIB, RITUXIMAB AND DEXAMETHASONE IN RELAPSED WALDENST... by M.-A. Dimopoulos, K. Amaador, M. C. Minnema, K. Nasserinejad, M. Kap, E. Kastritis, M. Gavriatopoulou, W. Kraan, M. E. D. Chamuleau, D. Deeren, L. Tick, J. K. Doorduijn, F. Offner, L. H. Böhmer, R. D. Liu, S. T. Pals, J. M. Vos, M. J. Kersten

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  5. 5

    S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN... by C. Hasselbalch Riley, M. Hutchings, S.-S. Yoon, Y. Koh, S. Manier, T. Facon, S. J. Harrison, J. Er, F. Volzone, A. Pinto, C. Montes, E. M. Ocio, A. Alfonso-Pierola, P. Rodriguez Otero, F. Offner, A. Guidetti, P. Corradini, C. Titouan, C. Hulin, C. Touzeau, P. Moreau, R. Popat, S. Leong, R. Mazza, A.-M. E. Bröske, I. Dekhtiarenko, H.-J. Helms, S. Belli, T. Vardar, T. Fauti, J. Eckmann, T. Moore, M. Schneider, W. Jacob, M. Weisser, C. Carlo-Stella

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  6. 6

    S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULT... by I. Dekhtiarenko, I. Lelios, J. Attig, N. Sleiman, D. Lazzaro, I. Clausen, N. Gräfe, H.-J. Helms, E. Schindler, S. Belli, T. Fauti, J. Eckmann, P. Umana, W. Jacob, M. Schneider, C. Hasselbalch Riley, M. Hutchings, S.-S. Yoon, Y Koh, S. Manier, T. Facon, S. J. Harrison, J. Er, F. Volzone, A. Pinto, C. Montes, E. M. Ocio, A. Alfonso-Pierola, P. Rodríguez Otero, F. Offner, A. Guidetti, P. Corradini, C. Titouan, C. Hulin, C. Touzeau, P. Moreau, R. Popat, S. Leong, R. Mazza, C. Carlo-Stella, A.-M. E. Bröske

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  7. 7

    B07 | LONG-TERM CLINICAL OUTCOMES WITH TISAGENLECLEUCEL IN HIGH-RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: 4-YEAR FOLLOW-UP FROM THE PHASE 2 ELARA STUDY by P.L. Zinzani, C. Thieblemont, M. Dreyling, M.J. Dickinson, J. Martínez-Lopez, A. Kolstad, J. Butler, M. Ghosh, L.L. Popplewell, J.C. Chavez, E. Bachy, K. Kato, H. Harigae, M.J. Kersten, C. Andreadis, P.A. Riedell, P.J. Ho, J.A. Pérez-Simón, A. Chen, L. Nastoupil, B. Von Tresckow, A.J.M. Ferreri, T. Teshima, P.E.M. Patten, J.P. Mcguirk, F. Offner, A. Viardot, R. Malladi, A. Zia, R. Awasthi, D. Germano, R.J. Ramos, P. Hsu, S.J. Schuster, N.H. Fowler

    Published in Haematologica (2025-09-01)
    Get full text
    Article


Search Tools: